Global Allogeneic Car T Cell Patent

The global allogeneic CAR T-cell therapy landscape is undergoing a dynamic transformation, driven by a robust patent ecosystem, next-gen gene editing technologies, and growing interest from biopharma innovators. As the market scales from USD 0.87 billion in... More

The global allogeneic CAR T-cell therapy landscape is undergoing a dynamic transformation, driven by a robust patent ecosystem, next-gen gene editing technologies, and growing interest from biopharma innovators. As the market scales from USD 0.87 billion in 2024 to USD 3.71 billion by 2034, intellectual property rights will play a pivotal role in shaping the competitive landscape. Less